Sammanfattning
Antimicrobial resistance poses a serious risk to contemporary healthcare since it reduces the number of bacterial illnesses that may be treated with antibiotics, particularly for patients with long-term conditions like cystic fibrosis (CF). People with a genetic predisposition to CF often have recurrent bacterial infections in their lungs due to a buildup of sticky mucus, necessitating long-term antibiotic treatment. Pseudomonas aeruginosa infections are a major cause of CF lung illness, and P. aeruginosa airway isolates are frequently resistant to many antibiotics. Bacteriophages (also known as phages), viruses that infect bacteria, are a viable substitute for antimicrobials to treat P. aeruginosa infections in individuals with CF. Here, we reviewed the utilization of P. aeruginosa bacteriophages both in vivo and in vitro, as well as in the treatment of illnesses and diseases, and the outcomes of the latter.
Originalspråk | engelska |
---|---|
Artikelnummer | 1051 |
Tidskrift | Viruses |
Volym | 16 |
Nummer | 7 |
Antal sidor | 28 |
ISSN | 1999-4915 |
DOI | |
Status | Publicerad - juli 2024 |
MoE-publikationstyp | A2 Granska artikel i en vetenskaplig tidskrift |
Bibliografisk information
Publisher Copyright:© 2024 by the authors.
Vetenskapsgrenar
- 11832 Mikrobiologi och virologi